Management of imatinib-resistant patients with chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Imatinib, approved in 2001, is a frontline therapy for chronic myelogenous leukemia (CML).
• Despite its efficacy, up to 33% of patients exhibit resistance or suboptimal response to imatinib.
• This necessitates the development of alternative treatment strategies and a deeper understanding of resistance mechanisms.

Purpose of the Study:

• To review the mechanisms underlying imatinib resistance in CML.
• To provide recommendations for monitoring treatment response and assessing milestones.
• To discuss management options for imatinib-resistant CML and upcoming therapies.

Main Methods:

• Literature review of studies on imatinib resistance in CML.
• Analysis of current guidelines for CML monitoring and management.
• Synthesis of data on second- and third-generation tyrosine kinase inhibitors.

Main Results:

• Identified key mechanisms of imatinib resistance.
• Outlined strategies for monitoring patient response and identifying resistance.
• Summarized available and emerging treatment options for resistant CML.

Conclusions:

• Effective management of imatinib-resistant CML requires understanding resistance mechanisms and appropriate monitoring.
• Second- and third-generation tyrosine kinase inhibitors offer viable alternatives for patients with suboptimal response.
• Careful assessment can prevent unnecessary treatment discontinuation and guide optimal patient care.